|
Decitabine-cedazuridine plus venetoclax (DEC-C+VEN) Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 2: 1
Top Sponsors
- Virginia Commonwealth University1
Indications
- High Risk Myeloproliferative Neoplasms1
- Relapsed/Refractory AML1
- High-risk Myelodysplastic Syndrome1
- Cancer1
Richmond, Virginia1 trial
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
Virginia Commonwealth University
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.